Spero Therapeutics, INC

Spero Therapeutics announced third quarter 2026 results, highlighting progress with its SP001 antibody program and extending its operational runway into late 2029.

Spero Therapeutics announced the resignation of director Patrick Vink and the appointment of William Ho, M.D., Ph.D., as a new Class II director.

Spero Therapeutics announced the upcoming retirement of its Chief Operating Officer, Timothy Keutzer, effective December 31, 2026, followed by a consulting arrangement.

Spero Therapeutics has entered into a new Open Market Sale Agreement with Jefferies LLC to potentially raise up to $100 million in common stock, while terminating a previous agreement with Cantor Fitzgerald.

Spero Therapeutics announced FDA approval for Utebzi, a $105 million financing deal, and a new licensing agreement for its SP001 program, extending cash runway into late 2029.

Spero Therapeutics has entered into an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody from Innovent Biologics, and secured $105 million in non-dilutive financing.

Spero Therapeutics' Q3 2026 Form 10-Q filing reveals FDA approval for Utebzi but highlights significant operating losses and a substantial accumulated deficit, necessitating future capital raises.

Spero Therapeutics announces FDA approval for Utebzi and a major collaboration with Innovent for its SP001 program, signaling a strategic shift and potential for future growth.

Spero Therapeutics reports Q3 2025 results, highlighting the successful Phase 3 PIVOT-PO trial for tebipenem HBr and strategic program terminations to focus resources.

Spero Therapeutics reported a reduced net loss in Q2 2025, driven by increased collaboration revenue from GSK and reduced R&D expenses following the successful early halt of its pivotal Phase 3 tebipenem HBr trial, while facing an ongoing SEC investigation and pipeline reprioritization.

Spero Therapeutics announces its Q1 2025 financial results, highlighting ongoing clinical development of tebipenem HBr and addressing concerns about its ability to continue as a going concern.

Spero Therapeutics halts development of SPR720 following disappointing interim Phase 2a results, leading to a strategic restructuring and workforce reduction.

Spero Therapeutics achieved a net income of $8.6 million in 2025, driven by collaboration revenue, as it streamlines its pipeline to focus on the FDA approval process for tebipenem HBr with GSK.

Spero Therapeutics' 10-K filing reveals a company in transition, suspending SPR720 and SPR206 development while focusing on tebipenem HBr amid financial challenges and a SEC investigation.

Spero Therapeutics outlines amendments to its 2019 Inducement Equity Incentive Plan and provides details on executive compensation, including stock options, RSUs, and cash bonuses.

Esther Rajavelu, See Remarks and a Director of Spero Therapeutics, Inc., sold 40,851 shares of common stock on November 6, 2026 for $1.04 per share.

William Ho, a Director of Spero Therapeutics, Inc., received 100,000 shares of common stock on November 10, 2026.

Debra Zack, Chief Medical Officer of Spero Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.

Spero Therapeutics Director Milind Deshpande acquired 10,000 restricted stock units and was granted an option to purchase 20,000 shares.

Kathleen Tregoning, a Director at Spero Therapeutics, Inc., reported the acquisition of 10,000 restricted stock units and 20,000 stock options.

Spero Therapeutics Director Cynthia Smith acquired 10,000 shares of common stock and was granted an option to purchase 20,000 shares.

Spero Therapeutics, Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and a significant increase in authorized common stock.

Spero Therapeutics is holding its annual stockholder meeting on June 12, 2025, and is soliciting votes on the election of directors, ratification of the company's accounting firm, executive compensation, and an amendment to the stock incentive plan.

Spero Therapeutics is holding its 2025 annual meeting virtually on June 12, 2025, to elect directors, ratify the selection of its accounting firm, approve executive compensation, and amend its stock incentive plan.

Spero Therapeutics' stockholders will vote on the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the stock incentive plan at the upcoming annual meeting.

Spero Therapeutics is holding its 2024 annual meeting of stockholders on May 29, 2024, to elect directors, ratify the selection of its accounting firm, approve executive compensation, and amend its stock incentive plan.

GSK PLC has filed an Amendment No. 9 to its Schedule 13D, reporting a decrease in its beneficial ownership of Spero Therapeutics, Inc. common stock to 16.4% due to an increase in Spero's outstanding shares.

Anson Funds Management LP and its affiliates reported a passive 2.9% beneficial ownership stake in Spero Therapeutics, Inc. as of June 30, 2025.